Adult acute lymphoblastic leukaemia

Renato Bassan, Gemma Gatta, Carlo Tondini, Roel Willemze

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Acute lymphoblastic leukaemia (ALL) in adults is a relatively rare neoplasm with a curability rate around 30% at 5 years. This consideration makes it imperative to dissect further the biological mechanisms of disease, in order to selectively implement an hitherto unsatisfactory success rate. The recognition of discrete ALL subtypes (some of which deserve specific therapeutic approaches, like T-lineage ALL (T-ALL) and mature B-lineage ALL (B-ALL)) is possible through an accurate combination of cytomorphology, immunophenotytpe and cytogenetic assays and has been a major result of clinical research studies conducted over the past 20 years. Two-three major prognostic groups are now easily identifiable, with a survival probability ranging from

Original languageEnglish
Pages (from-to)223-261
Number of pages39
JournalCritical Reviews in Oncology/Hematology
Volume50
Issue number3
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics
Research
Neoplasms
Therapeutics

Keywords

  • Acute lymphoblastic leukaemia (ALL)
  • B-lineage ALL
  • Clinical and laboratory issues
  • T-lineage ALL

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Adult acute lymphoblastic leukaemia. / Bassan, Renato; Gatta, Gemma; Tondini, Carlo; Willemze, Roel.

In: Critical Reviews in Oncology/Hematology, Vol. 50, No. 3, 06.2004, p. 223-261.

Research output: Contribution to journalArticle

Bassan, Renato ; Gatta, Gemma ; Tondini, Carlo ; Willemze, Roel. / Adult acute lymphoblastic leukaemia. In: Critical Reviews in Oncology/Hematology. 2004 ; Vol. 50, No. 3. pp. 223-261.
@article{4dfa492f0d3a40278d617b7059955239,
title = "Adult acute lymphoblastic leukaemia",
abstract = "Acute lymphoblastic leukaemia (ALL) in adults is a relatively rare neoplasm with a curability rate around 30{\%} at 5 years. This consideration makes it imperative to dissect further the biological mechanisms of disease, in order to selectively implement an hitherto unsatisfactory success rate. The recognition of discrete ALL subtypes (some of which deserve specific therapeutic approaches, like T-lineage ALL (T-ALL) and mature B-lineage ALL (B-ALL)) is possible through an accurate combination of cytomorphology, immunophenotytpe and cytogenetic assays and has been a major result of clinical research studies conducted over the past 20 years. Two-three major prognostic groups are now easily identifiable, with a survival probability ranging from",
keywords = "Acute lymphoblastic leukaemia (ALL), B-lineage ALL, Clinical and laboratory issues, T-lineage ALL",
author = "Renato Bassan and Gemma Gatta and Carlo Tondini and Roel Willemze",
year = "2004",
month = "6",
doi = "10.1016/j.critrevonc.2003.11.003",
language = "English",
volume = "50",
pages = "223--261",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Adult acute lymphoblastic leukaemia

AU - Bassan, Renato

AU - Gatta, Gemma

AU - Tondini, Carlo

AU - Willemze, Roel

PY - 2004/6

Y1 - 2004/6

N2 - Acute lymphoblastic leukaemia (ALL) in adults is a relatively rare neoplasm with a curability rate around 30% at 5 years. This consideration makes it imperative to dissect further the biological mechanisms of disease, in order to selectively implement an hitherto unsatisfactory success rate. The recognition of discrete ALL subtypes (some of which deserve specific therapeutic approaches, like T-lineage ALL (T-ALL) and mature B-lineage ALL (B-ALL)) is possible through an accurate combination of cytomorphology, immunophenotytpe and cytogenetic assays and has been a major result of clinical research studies conducted over the past 20 years. Two-three major prognostic groups are now easily identifiable, with a survival probability ranging from

AB - Acute lymphoblastic leukaemia (ALL) in adults is a relatively rare neoplasm with a curability rate around 30% at 5 years. This consideration makes it imperative to dissect further the biological mechanisms of disease, in order to selectively implement an hitherto unsatisfactory success rate. The recognition of discrete ALL subtypes (some of which deserve specific therapeutic approaches, like T-lineage ALL (T-ALL) and mature B-lineage ALL (B-ALL)) is possible through an accurate combination of cytomorphology, immunophenotytpe and cytogenetic assays and has been a major result of clinical research studies conducted over the past 20 years. Two-three major prognostic groups are now easily identifiable, with a survival probability ranging from

KW - Acute lymphoblastic leukaemia (ALL)

KW - B-lineage ALL

KW - Clinical and laboratory issues

KW - T-lineage ALL

UR - http://www.scopus.com/inward/record.url?scp=2942560263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942560263&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2003.11.003

DO - 10.1016/j.critrevonc.2003.11.003

M3 - Article

VL - 50

SP - 223

EP - 261

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -